Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

ABSTRACT:

Importance

Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer.

Objective

To understand how WES data affect therapeutic decision making in patients with advanced cancer and to identify novel biomarkers of response.

Design, setting, and patients

Patients with metastatic and treatment-resistant cancer were prospectively enrolled at a single academic center for paired metastatic tumor and normal tissue WES during a 19-month period (February 2013 through September 2014). A comprehensive computational pipeline wa

SUBMITTER: Beltran H 

PROVIDER: S-EPMC4505739 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature